Incyte (INCY) Stock Analysis & AI Equity Report
Incyte (INCY) overview
Incyte (INCY) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 5,141m and operating profit of USD 1,515m; the year-end share price was 98.77 USD and market capitalisation was USD 19,602m. Incyte is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Incyte's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Incyte
Incyte discovers, develops and commercializes proprietary therapeutics, with programs and approved medicines in hematology, oncology, and inflammation and autoimmunity. Its products include JAKAFI for certain blood cancers and graft-versus-host disease. Incyte markets JAKAFI in the United States through a specialty sales force and commercial team, while Novartis holds rights to ruxolitinib in other countries.
Generate the Incyte report
Incyte is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Incyte and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Incyte
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.